PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; as well as holds a patent and know-how license agreement with The Queen’s University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Metrics to compare | PHRM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHRMPeersSector | |
---|---|---|---|---|
P/E Ratio | −27.7x | −0.9x | −0.5x | |
PEG Ratio | −0.35 | 0.00 | 0.00 | |
Price/Book | 33.6x | 0.8x | 2.6x | |
Price / LTM Sales | - | 0.4x | 3.3x | |
Upside (Analyst Target) | - | 57.1% | 40.6% | |
Fair Value Upside | Unlock | 5.5% | 5.3% | Unlock |